Hanmi R&D becomes stronger through cooperation with partners.
- efocipegtrutide (LAPSTriple agonist)
- sonefpeglutide (LAPSGLP-2 analog)
- efpegerglucagon (LAPSGlucagon analog)
- HM97662 (EZH1/2 inhibitor)
- BH3120 (PD-L1/4-1BB BsAb)
- HM15275 (LA-GLP/GIP/GCG)
- HM16390 (LAPSIL-2 analog)
- HM17321 (LA-UCN2)
- HM99462 (SOS1 inhibitor)
- LAPS Glucagon Combo
BH3120 (PD-L1/4-1BB BsAb)
Oncology
Preclinical
Overview
PD-L1/4-1BB bispecific antibody with well-balanced efficacy and safety
Description
BH3120 is a heterodimeric bispecific antibody
PENTAMBODY
designed to target 4-1BB and PD-L1 simultaneously to stimulate anti-tumor immune response either by inhibition of an immune checkpoint mechanism and by activation of a co-stimulatory signal in tumor microenvironment (TME) focused manner.
Non-clinical observations with BH3120, either as a monotherapy or in combination settings, consistently explain strong anti-tumor T cell activities in tumor tissue specific manner with clear dose dependency, while systemic immune response is minimally modulated.
These properties support further evaluation of the immune-modulating bispecific antibody, and BH3120 will be studied as a therapeutic candidate with multiple types of solid tumors.
Non-clinical observations with BH3120, either as a monotherapy or in combination settings, consistently explain strong anti-tumor T cell activities in tumor tissue specific manner with clear dose dependency, while systemic immune response is minimally modulated.
These properties support further evaluation of the immune-modulating bispecific antibody, and BH3120 will be studied as a therapeutic candidate with multiple types of solid tumors.
Dual cancer immunotherapy targets
- Inhibition of PD-1/PD-L1, T cell- co-stimulatory signaling by 4-1BB agonism
- Conditional, PD-L1 binding dependent, 4-1BB activation in tumor tissue specific manner
- Well balanced efficacy and safety in mono and combination settings
Publications